https://www.thebody.com/category/financial-issues-hiv/tag/news-analysis
Financial Issues

News Analysis

The Latest

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents Img

How Activists Uncovered CDC's Ownership of Truvada PrEP Patents

The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.

By Charles Sanchez
If Nobody Slashes the Price of Truvada for PrEP, What Happens Next? Img

If Nobody Slashes the Price of Truvada for PrEP, What Happens Next?

Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.

By Tim Murphy
Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment? Img

Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

Advocates say the price is a step in the right direction. But does it go far enough?

By Tim Murphy
Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find Img

Sticker Shock: PrEP Is Not Cost-Effective at Current Price, Health Economists Find

But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.

By Sony Salzman
PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference Img

PrEP Pricing Is the Elephant in the Room at the CDC National HIV Prevention Conference

In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.

By Sony Salzman
The Trump Administration's Drug Pricing Proposals for People With HIV, Explained Img

The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.

By Tim Murphy
In the Senate, the 340B Drug Pricing Program Finds More Backers Than Detractors Img

In the Senate, the 340B Drug Pricing Program Finds More Backers Than Detractors

Despite the tremendous success of the program -- or perhaps because of it -- and courtesy of a substantial lobbying push from the Pharmaceutical Research and Manufacturers of America (PhRMA), the 340B program has found itself under close scrutiny by ...

By AIDS United
Administration Attacks on Drug Pricing Program Have Advocates Worried Img

Administration Attacks on Drug Pricing Program Have Advocates Worried

A program that lowers drug costs for Ryan White clinics, community health centers, family planning clinics, and hospitals serving low-income patients is under attack by Republicans in Congress and the Trump Administration.

By Richard Sorian for AIDS United
Gilead COMPASS Initiative panel discussion participants (L-R): Dr. Michael Mugavero (UAB School of Public Health), Nic Carlisle (Southern AIDS Coalition) and Kathie Hiers (AIDS Alabama) with moderator Douglas Brooks (Gilead Sciences) at The Harbert Center

Gilead Will Help Fund the Fight Against HIV in Southern States. Is That a Mixed Blessing?

Big Pharma money can beef up public health efforts. But it can also distract from unchecked drug pricing -- and from government negligence.

By Tim Murphy
Universal Health Care and Prescription Drug Pricing Img

Universal Health Care and Prescription Drug Pricing

Reining in prescription drug prices isn't so much a potential benefit of universal health care, but rather a factor in its affordability and success.

By Tim Horn for Treatment Action Group